DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,222.261 B2 Katamreddy Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,222.261 B2 Katamreddy Et Al USOO8222261 B2 (12) United States Patent (10) Patent No.: US 8,222.261 B2 Katamreddy et al. (45) Date of Patent: Jul. 17, 2012 (54) CHEMICAL COMPOUNDS (56) References Cited (75) Inventors: Subba R Katamreddy, Durham, NC U.S. PATENT DOCUMENTS (US); Richard Dama Caldwell, 2004/0176400 A1* 9/2004 Capelli et al. ............ 514,264. 11 Durham, NC (US); Dennis Heyer Durham,s NC (US);s Vincente Samano,s OTHER PUBLICATIONS Durham, NC (US); James Benjamin Fyfe et al GPR119 agonists as potential new oral agents for the Thompson, Durham, NC (US); Andrew treatment of type 2 diabetes and obesity Expert Opin. Drug Discov., J. Carpenter. Durham, NC (US); RaWa A. i.e.ystematic tic ReviewKeview of DrugLJrug Thlnerapy to LelayDelav oof hspp. R E. P. Nc Prevent Type 2 Diabetes’ Diabetes Care, 28(3), p. 736-744, 2005.* (US); ric ugene Soros, Jurnam, Stella et al Prodrugs: Challenges and Rewards, Part 1 Biotechnol (US); Brian D Thompson, Durham, NC ogy: Pharmaceutical Aspects, p. 24, 2007.* (US) Vippagunta et al 'Crystalline Solids' Advanced Drug Delivery Reviews, vol. 48, p. 3-26, 2001.* (73) Assignee: GlaxoSmithKline, LLC, Philadelphia, insulinMayet, SecretionS., et al. inGPR119 insulin-producing activation increasescells and isolatedglucose-dependent rat islets, PA (US) Diabetologia, V48 NSuppl. 2005 p. A166. Fyfe, Matthew, et al., “Discovery of novel, orally active, synthetic (*) Notice: Subject to any disclaimer, the term of this GPR119 agonists as potential agents for treatment of obesity and patent is extended or adjusted under 35 isited metabolic disorders.” Diabetes, V55. NSuppl. Jun. 2006, U.S.C. 154(b) by 652 days. Soga, T, et al., “Lysophosphatidylcholine& 8 enhances glucose-depen dent insulin Secretion via an orphan G-protein-coupled receptor.” (21) Appl. No.: 12/373,524 Biochemical and Biophysical Research Communications, V326, N4. Jan. 28, 2005, pp. 744-751. 1-1. Overton, Hilary, et al., “Deorphanization of a G protein-coupled (22) Filed: Jan. 13, 2009 receptor for eleoylethanoamide and its use in the discovery of Small molecule hypophagic agents.” Cell Metabolism, V3, N3, Mar. 2006, (65) Prior Publication Data pp. 167-175. US 2009/0318477 A1 Dec. 24, 2009 * cited by examiner O O Primary Examiner — Brandon Fetterolf Related U.S. Application Data Assistant Examiner — Christopher R Stone (60) Provisional application No. 60/807.225, filed on Jul. (74) Attorney, Agent, or Firm — Bonnie L. Deppenbrock 13, 2006. (57) ABSTRACT 51) Int. Cl. The present invention relates to novel compounds that are (51) A 6LX3/59 (2006.01) useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the (52) U.S. Cl. ...................................... 51.4/265.1 methods for the making and use of Such compounds. (58) Field of Classification Search ................ 51.4/265.1 See application file for complete search history. 32 Claims, 22 Drawing Sheets U.S. Patent Jul. 17, 2012 Sheet 1 of 22 US 8,222.261 B2 FIGURE 1 : Vehicle 1. 3 10 30 60 Example 1 (mg/kg) U.S. Patent Jul. 17, 2012 Sheet 2 of 22 US 8,222,261 B2 FIGURE 2 SOO 4OO 300 2OO 100 Vehicle 1 3 O 3O 60 Example 1 (mg/kg) U.S. Patent Jul. 17, 2012 Sheet 3 of 22 US 8,222.261 B2 FIGURE 3 2 O O 1. 5 O 1. O O 5 O Example 1 Example 1 WT U.S. Patent Jul. 17, 2012 Sheet 4 of 22 US 8,222.261 B2 FIGURE 4 SOO 4. O O 23OO OO W U.S. Patent Jul. 17, 2012 Sheet 5 of 22 US 8,222,261 B2 FIGURE 5 200 8 O 1. 5 O 1. 4. O 1. 2 O O O X Ko wt U.S. Patent Jul. 17, 2012 Sheet 6 of 22 US 8,222.261 B2 FIGURE 6 O, 5 O. 4. O, 3 0. 2 0. 1. Example 1 Vehicle Example 1 ko wt U.S. Patent Jul. 17, 2012 Sheet 7 of 22 US 8,222.261 B2 FIGURE 7 Post Pe. Post i Vehicle Example 1 U.S. Patent Jul. 17, 2012 Sheet 8 of 22 US 8,222.261 B2 FIGURE 8 1. sO 1. 4. O 1. pe T. P. U.S. Patent Jul. 17, 2012 Sheet 9 of 22 US 8,222.261 B2 FIGURE 9 | 1. r rost U.S. Patent Jul. 17, 2012 Sheet 10 of 22 US 8,222.261 B2 FIGURE 10 U.S. Patent Jul. 17, 2012 Sheet 11 of 22 US 8,222.261 B2 FIGURE 11 --Vehicle -0-1 mg/kg. Example 1 -0-10mg/kg. Example 1 U.S. Patent Jul. 17, 2012 Sheet 12 of 22 US 8,222,261 B2 FIGURE 12 rose rear u-er u-er u-a-r-rr u-er G S S4 na E --Vehicle w -0-1 g/kg example 1 9. -0-10 g/kg Example 1 2S S. C O Y O K d C C C h 20 a-2S S-1 3 NS 15 --- - ... - - - - - - - ' ' ... t O O 2O 30 40 50 6O 70 8O Time (min) U.S. Patent Jul. 17, 2012 Sheet 13 of 22 US 8,222,261 B2 FIGURE 13 g --Vehicle St 2000 -o-1 mg/kg. Example 1 S -0-10mg/kg. Example 1 1500 3. s is 1000 -- .------ . ...---- O 10 2O 3O 40 50 60 70 80 9 Time (min) U.S. Patent Jul. 17, 2012 Sheet 14 of 22 US 8,222.261 B2 FIGURE 14 3 S O 3 O O -- Vehicle -O-Example 1 2 5 O 2 O O 150 OO U.S. Patent Jul. 17, 2012 Sheet 15 of 22 US 8,222.261 B2 FIGURE 15 -U-Veh -O-Example 1 U.S. Patent Jul. 17, 2012 Sheet 16 of 22 US 8,222.261 B2 FIGURE 16 250 -- Vehide 2OO -O-Example 1 -0- DPPV 150 100 50 Time (minutes) U.S. Patent Jul. 17, 2012 Sheet 17 of 22 US 8,222,261 B2 FIGURE 17 1OOOO 8O O O 6000 2000 DPPIV Example 1 DPPV ko wit U.S. Patent Jul. 17, 2012 Sheet 18 of 22 US 8,222,261 B2 FIGURE 18 -m mmammariner am-Y: * ' a r -a-Vehicle -(-Example 1 U.S. Patent Jul. 17, 2012 Sheet 19 of 22 US 8,222.261 B2 FIGURE 19 Time (min) U.S. Patent Jul. 17, 2012 Sheet 20 of 22 US 8,222.261 B2 FIGURE 20 4N E 5.N " A. t U g O Time (min) U.S. Patent Jul. 17, 2012 Sheet 21 of 22 US 8,222,261 B2 FIGURE 21 SO 110 s70 a. 105 S G 360 5 100 50 s 95 s 30 90 2 O 8 S Vehicle Example Vehicle Example 1 east Treatment U.S. Patent Jul. 17, 2012 Sheet 22 of 22 US 8,222.261 B2 FIGURE 22 6 -- Vehicle e -0- Example 1 E 5 N 94 N 3 N 2 Qu US 8,222,261 B2 1. 2 CHEMICAL COMPOUNDS blood glucose levels. About 49% of individuals with Type II diabetes require oral medication(s), about 40% of individuals This application is filed pursuant to 35 U.S.C. S371 as a require insulin injections or a combination of insulin injec United States National Phase Application of International tions and oral medication(s), and about 10% of individuals Application No. PCT/US2007/073352 filed Jul. 12, 2007, 5 may use diet and exercise alone. which claims priority from U.S. 60/807.225 filed Jul. 13, Current therapies for diabetes mellitus include: insulin; 2006. insulin secretagogues, such as Sulphonylureas, which increase insulin secretion from pancreatic B-cells; glucose FIELD OF THE INVENTION lowering effectors, such as mefformin which reduce glucose 10 production from the liver; activators of the peroxisome pro The present invention relates to novel compounds that are liferator-activated receptor-Y(PPAR-Y), such as the thiazo useful in the treatment and prevention of metabolic disorders, lidinediones, which enhances insulin action; and C-glucosi including diabetes mellitus (Type I and Type II), obesity, and dase inhibitors which interfere with gut glucose production. related disorders, and also includes methods for making, There are, however, deficiencies associated with currently pharmaceutical compositions containing, and therapeutic 15 available treatments, including hypoglycemic episodes, uses for Such compounds. weight gain, loss in responsiveness to therapy over time, gastrointestinal problems, and edema. BACKGROUND OF THE INVENTION There are several areas at which research is being targeted in order to bring new, more effective, therapies to the market Diabetes mellitus is an ever-increasing threat to human place. For example, on-going research includes exploring a health. For example, in the United States current estimates reduction in excessive hepatic glucose production, enhancing maintain that about 16 million people suffer from diabetes the pathway by which insulin transmits its signal to the cells mellitus. Such that they take up glucose, enhancing glucose-stimulated Type I diabetes, also known as insulin-dependent diabetes insulin Secretion from the pancreatic B-cells, and targeting mellitus (IDDM), is caused by the autoimmune destruction of obesity and associated problems with fat metabolism and the insulin producing pancreatic f-cells, and necessitates 25 accumulation. regular administration of exogenous insulin. Without insulin, GIP and GLP-1 are peptides, known as incretins, secreted cells cannot absorb Sugar (glucose), which they need to pro from enteroendocrine K and L cells respectively in response duce energy. Symptoms of Type I diabetes usually start in to ingestion of nutrients, and have a wide variety of physi childhood or young adulthood. People often seek medical ological effects that have been described in numerous publi help because they are seriously ill from Sudden symptoms of 30 cations over the past two decades.
Load more

Recommended publications
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark
    A Service of Leibniz-Informationszentrum econstor Wirtschaft Leibniz Information Centre Make Your Publications Visible. zbw for Economics Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas Working Paper Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark ZEW Discussion Papers, No. 10-062 Provided in Cooperation with: ZEW - Leibniz Centre for European Economic Research Suggested Citation: Kaiser, Ulrich; Mendez, Susan J.; Rønde, Thomas (2010) : Regulation of pharmaceutical prices: Evidence from a reference price reform in Denmark, ZEW Discussion Papers, No. 10-062, Zentrum für Europäische Wirtschaftsforschung (ZEW), Mannheim This Version is available at: http://hdl.handle.net/10419/41440 Standard-Nutzungsbedingungen: Terms of use: Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Documents in EconStor may be saved and copied for your Zwecken und zum Privatgebrauch gespeichert und kopiert werden. personal and scholarly purposes. Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle You are not to copy documents for public or commercial Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich purposes, to exhibit the documents publicly, to make them machen, vertreiben oder anderweitig nutzen. publicly available on the internet, or to distribute or otherwise use the documents in public. Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, If the documents have been made available under an Open gelten abweichend von diesen Nutzungsbedingungen die in der dort Content Licence (especially Creative Commons Licences), you genannten Lizenz gewährten Nutzungsrechte. may exercise further usage rights as specified in the indicated licence. www.econstor.eu Dis cus si on Paper No. 10-062 Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark Ulrich Kaiser, Susan J.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0058292 A1 Tawakol (43) Pub
    US 2008.0058292A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0058292 A1 Tawakol (43) Pub. Date: Mar. 6, 2008 (54) METHOD FOR INCREASING HDL AND A6II 3 L/455 (2006.01) HDL-2B LEVELS A6II 3 L/60 (2006.01) 76 ). A6IP 3/00 (2006.01) (76) Inventor: Raif Tawakol, Merced, CA (US) (52) U.S. Cl. ............................................ 514/161; 514/356 Correspondence Address: RONALD V. DAVIDGE 9900 STRLING ROAD (57) ABSTRACT SUTE 219 COOPER CITY, FL 33024 (US) The present invention provides a method for reducing flush (21) Appl. No.: 11/899,284 ing in a patient and for for increasing HDL and/or HDL-2b levels in a patient, with compositions being administered to 22) Filed: Sep.p 5, 2007 the ppatient onlyy twice a day,y from 30 to 60 minutes after lunch and 30 to 60 minutes after dinner. In some embodi Related U.S. Application Data ments, the compositions include an adipocyte G-protein (63) Continuation-in-part of application No. 10/977.508, antagonist, a PPAR-c. agonist , and a PPAR-y agonist in filed on Oct. 29, 2004. amounts effective in to provide a synergistic therapeutic HDL increasing effect, and/or a synergistic therapeutic (60) Provisional application No. 60/515,891, filed on Oct. HDL-2b increasing effect. 29, 2003. Publication Classification (51) Int. Cl. BREAKFAST LUNCH DINNER SLEEP Patent Application Publication Mar. 6, 2008 US 2008/0058292 A1 BREAKFAST LUNCH DINNER SLEEP FIG. 1 BREAKFAST LUNCH DINNER SLEEP FIG. 2 US 2008/0058292 A1 Mar. 6, 2008 METHOD FOR INCREASING HDL AND HDL-2B ingly, the combination of an adipocyte G-protein antagonist, LEVELS a peroxisome proliferator-activated receptor-C.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0155091A1 Huval Et Al
    US 2002O155091A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0155091A1 Huval et al. (43) Pub. Date: Oct. 24, 2002 (54) COMBINATION THERAPY FOR TREATING Publication Classification HYPERCHOLESTEROLEMIA (51) Int. Cl." ..................................................... A61K 31/74 (75) Inventors: Chad Cori Huval, Somerville, MA (US); Stephen Randall Holmes-Farley, (52) U.S. Cl. .......................................................... 424/78.29 Arlington, MA (US); John S. Petersen, Acton, MA (US); Pradeep K. Dhal, Westford, MA (US) (57) ABSTRACT Correspondence Address: HAMILTON, BROOK, SMITH & REYNOLDS, The invention relates to methods for treating hypercholes P.C. terolemia and atherosclerosis, and reducing Serum choles 530 VIRGINA ROAD terol in a mammal. The methods of the invention comprise P.O. BOX 91.33 administering to a mammal a first amount of a bile acid CONCORD, MA 01742-9133 (US) Sequestrant compound which is an unsubstituted polydial lylamine polymer and a Second amount of a cholesterol (73) Assignee: GelTex Pharmaceuticals, Inc., lowering agent. The first and Second amounts together Waltham, MA comprise a therapeutically effective amount. (21) Appl. No.: 10/025, 184 The invention further relates to pharmaceutical composi tions useful for the treatment of hypercholesterolemia and (22) Filed: Dec. 19, 2001 atherOSclerosis, and for reducing Serum cholesterol. The pharmaceutical compositions comprise a combination of a Related U.S. Application Data first amount of an unsubstituted polydiallylamine polymer compound and a Second amount of a cholesterol-lowering (63) Continuation of application No. 09/311,103, filed on agent. The first and Second amounts comprise a therapeuti May 13, 1999, now Pat. No. 6,365,186, which is a cally effective amount.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs
    Molecules 2016, 21, 75; doi:10.3390/molecules21010075 S1 of S110 Supplementary Materials: Chemical Structure-Related Drug-Like Criteria of Global Approved Drugs Fei Mao 1, Wei Ni 1, Xiang Xu 1, Hui Wang 1, Jing Wang 1, Min Ji 1 and Jian Li * Table S1. Common names, indications, CAS Registry Numbers and molecular formulas of 6891 approved drugs. Common Name Indication CAS Number Oral Molecular Formula Abacavir Antiviral 136470-78-5 Y C14H18N6O Abafungin Antifungal 129639-79-8 C21H22N4OS Abamectin Component B1a Anthelminithic 65195-55-3 C48H72O14 Abamectin Component B1b Anthelminithic 65195-56-4 C47H70O14 Abanoquil Adrenergic 90402-40-7 C22H25N3O4 Abaperidone Antipsychotic 183849-43-6 C25H25FN2O5 Abecarnil Anxiolytic 111841-85-1 Y C24H24N2O4 Abiraterone Antineoplastic 154229-19-3 Y C24H31NO Abitesartan Antihypertensive 137882-98-5 C26H31N5O3 Ablukast Bronchodilator 96566-25-5 C28H34O8 Abunidazole Antifungal 91017-58-2 C15H19N3O4 Acadesine Cardiotonic 2627-69-2 Y C9H14N4O5 Acamprosate Alcohol Deterrant 77337-76-9 Y C5H11NO4S Acaprazine Nootropic 55485-20-6 Y C15H21Cl2N3O Acarbose Antidiabetic 56180-94-0 Y C25H43NO18 Acebrochol Steroid 514-50-1 C29H48Br2O2 Acebutolol Antihypertensive 37517-30-9 Y C18H28N2O4 Acecainide Antiarrhythmic 32795-44-1 Y C15H23N3O2 Acecarbromal Sedative 77-66-7 Y C9H15BrN2O3 Aceclidine Cholinergic 827-61-2 C9H15NO2 Aceclofenac Antiinflammatory 89796-99-6 Y C16H13Cl2NO4 Acedapsone Antibiotic 77-46-3 C16H16N2O4S Acediasulfone Sodium Antibiotic 80-03-5 C14H14N2O4S Acedoben Nootropic 556-08-1 C9H9NO3 Acefluranol Steroid
    [Show full text]
  • The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis
    International Journal of Molecular Sciences Review The Role of PPAR and Its Cross-Talk with CAR and LXR in Obesity and Atherosclerosis Pengfei Xu 1,2, Yonggong Zhai 1,2,* and Jing Wang 3,* 1 Beijing Key Laboratory of Gene Resource and Molecular Development, College of Life Sciences, Beijing Normal University, Beijing 100875, China; [email protected] 2 Key Laboratory for Cell Proliferation and Regulation Biology of State Education Ministry, College of Life Sciences, Beijing Normal University, Beijing 100875, China 3 Department of Biology Science and Technology, Baotou Teacher’s College, Baotou 014030, China * Correspondence: [email protected] (Y.Z.); [email protected] (J.W.); Tel.: +86-10-5880-6656 (Y.Z.); +86-186-482-6849 (J.W.) Received: 26 March 2018; Accepted: 19 April 2018; Published: 23 April 2018 Abstract: The prevalence of obesity and atherosclerosis has substantially increased worldwide over the past several decades. Peroxisome proliferator-activated receptors (PPARs), as fatty acids sensors, have been therapeutic targets in several human lipid metabolic diseases, such as obesity, atherosclerosis, diabetes, hyperlipidaemia, and non-alcoholic fatty liver disease. Constitutive androstane receptor (CAR) and liver X receptors (LXRs) were also reported as potential therapeutic targets for the treatment of obesity and atherosclerosis, respectively. Further clarification of the internal relationships between these three lipid metabolic nuclear receptors is necessary to enable drug discovery. In this review, we mainly summarized the cross-talk of PPARs-CAR in obesity and PPARs-LXRs in atherosclerosis. Keywords: PPAR; CAR; LXR; obesity; atherosclerosis 1. Introduction Obesity is a lipid metabolic disturbance that has been growing across the world for nearly half a century.
    [Show full text]
  • WO 2016/127019 A2 11 August 2016 (11.08.2016) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2016/127019 A2 11 August 2016 (11.08.2016) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/445 (2006.01) A61K 31/426 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/US20 16/0 16694 KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (22) International Filing Date: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, 5 February 2016 (05.02.2016) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, (25) Filing Language: English TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (26) Publication Language: English (84) Designated States (unless otherwise indicated, for every (30) Priority Data: kind of regional protection available): ARIPO (BW, GH, 62/1 13,134 6 February 2015 (06.02.2015) US GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicant: INTERCEPT PHARMACEUTICALS, INC. TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, [US/US]; 450 W.
    [Show full text]